Psoriatic Immune Response to Tildrakizumab

• Status: Not yet recruiting
• Trial end date: 2025-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Francisco
• Collaborator: Sun Pharmaceutical Industries Limited
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria:

• 18 years of age or older

• Patients with moderate-severe psoriasis or > 5% body surface area affected.

Exclusion Criteria:

• taking systemic immunosuppressives in the last 4 weeks

• pregnancy

• severe immunodeficiency (either from genetic or infectious causes).

• tuberculosis or other active serious infection

• active systemic malignancy.

• breast-feeding

• Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.